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The TWEAK/Fn14 pathway is now well-known for its involvement in the modulation of
inflammation in various human autoimmune/chronic inflammatory diseases (AICID) includ-
ing lupus, rheumatoid arthritis, and multiple sclerosis. A panel of data is now available
concerning TWEAK expression in tissues or biological fluids of patients suffering from
AICID, suggesting that it could be a promising biological marker in these diseases. Evi-
dences from several teams support the hypothesis that blocking TWEAK/Fn14 pathway
is an attractive new therapeutic lead in such diseases and clinical trials with anti-TWEAK-
blocking antibodies are in progress. In this mini-review we discuss the potential use of
TWEAK quantification in AICD management in routine practice and highlight the challenge
of standardizing data collection to better estimate the clinical utility of such a biological
parameter.
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INTRODUCTION
Autoimmune and chronic inflammatory diseases (AICID) includ-
ing rheumatoid arthritis (RA), multiple sclerosis (MS), systemic
lupus erythematosus (SLE), or systemic sclerosis (SSc) constitute
an important medical, social, and economic problem. The preva-
lence of AICID is estimated to be more than 3% in the adult
population (1) and despite scientific progress in the past decade,
identification of new reliable markers for diagnosis, prognosis, and
prevention of hospitalization is still necessary.
TWEAK is a pleiotropic and multifunctional cytokine that
regulates inflammatory pathways by inducing multiple cellular
responses depending on the cell type and its micro-environment.
During tissue repair and remodeling, the biological activity of
TWEAK is complex and even dual: after acute injury, TWEAK
promotes tissue regeneration especially by stimulating progenitor
cells, but in chronic diseases where TWEAK is persistently acti-
vated, it alters tissue repair in part by inhibiting differentiation of
the same progenitor cells (2). A growing body of data points to
the involvement of the TWEAK/Fn14 pathway in inflammation
in various human AICID including SLE, RA, and MS. It is now
admitted that TWEAK plays a role in the physiopathology of such
diseases and the first clinical trials are in progress, based on anti-
TWEAK-blocking therapies during RA or SLE (3, 4). Nevertheless
it remains to be proven that the assessment of TWEAK levels in
tissues or biological fluids is of interest for the management of
patients suffering from AICID. In this article we propose to review
the available data on TWEAK quantification in human AICID
and to discuss the potential place and the modalities of TWEAK
evaluation in the diagnosis and/or the follow-up of AICID.
TWEAK EVALUATION IN AICID: WHY, WHEN, AND
WHAT FOR?
Biomarkers in medicine have gained immense scientific and clini-
cal interest in recent years. Biomarkers are potentially useful in the
context of primary, secondary, and tertiary prevention. An ideal
biomarker should be safe to assess, easy to measure and associated
with acceptable costs. Additionally, the biomarker should have
“good performance characteristics” (i.e., sensitivity, specificity,
positive- and negative-predictive values) and there should be sci-
entific evidence to suggest that biomarker modification influences
disease outcome.
In AICID, various serum circulating auto-antibodies are widely
used as reliable markers for diagnostic or sometimes prognos-
tic evaluation. Nevertheless the identification of new markers
to evaluate inflammatory activity of the disease, to predict dis-
ease flare or to monitor the clinical response to biotherapy
remains necessary.
The idea that TWEAK could be such a biomarker in AICID is
suggested by its role in the modulation of inflammation in AICID
both in animal models and in human pathologies. Moreover, in
the past decade, various research groups have shown modulation
of TWEAK expression in tissue and biological fluids of patients
suffering from AICID.
FOR ESTABLISHING A DIAGNOSIS OF AICID
Very few data are available concerning the diagnostic potential
of soluble TWEAK in AICID. Among them, urinary TWEAK
(uTWEAK) has been proposed by Schwartz and colleagues as a
biomarker for lupus nephritis (LN) as they showed that it is ele-
vated in subjects with LN at diagnosis compared with those with
SLE but no renal disease (5). Moreover uTWEAK levels were better
at distinguishing LN and non LN-SLE than anti-DNA antibodies
and complement levels. Schwartz et al. also reported that serum
TWEAK (sTWEAK) levels and the urine/sTWEAK ratio were not
better markers for LN than the less invasive uTWEAK. It is intrigu-
ing to note in this work that sTWEAK levels were significantly
lower in SLE patients than in healthy individuals. Later, El-Shehaby
et al. have also shown that uTWEAK levels positively correlate with
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renal involvement during SLE with a positive predictive value of
the marker of 93% for kidney inflammation (6).
FOR FOLLOWING-UP DISEASE ACTIVITY
Autoimmune and chronic inflammatory diseases are chronic dis-
eases that usually fluctuate between periods of remission (little/no
symptoms) and unpredictable flare-ups (worsening symptoms).
In this context, the ability to predict the severity of disease and
the outcome of flares should allow tertiary prevention of disease
complications. In LN, renal biopsy remains the gold standard for
assessment of disease activity but because of its invasive modali-
ties, this approach cannot be used repeatedly in clinical practice
to follow-up disease activity. In this context, uTWEAK has been
shown to correlate with the degree of clinical disease activity dur-
ing LN (5) and fluctuations of uTWEAK levels were found to
reflect LN flares. uTWEAK could thus represent an interesting
biological tool if the diagnosis of a flare is in doubt.
In RA, auto-immunity and chronic inflammation leads to
the destruction of cartilage and bone in the joints. The rela-
tionship between TWEAK and arthritis has been supported by
anti-inflammatory and anti-angiogenic effects of TWEAK inhibi-
tion in a mouse model of collagen-induced arthritis (7, 8). Park
et al. showed for the first time that sTWEAK levels were higher
in RA patients than in healthy controls (9). Moreover, sTWEAK
levels in RA patients positively correlated with the DAS 28 disease
activity scores (9).
In 2009, Yanaba et al. described for the first time elevated
sTWEAK levels in patients suffering from another AICID, SSc,
a generalized connective tissue disorder characterized by sclerotic
changes in the skin and internal organs. The longitudinal study
of sTWEAK levels performed in this study showed that these high
soluble TWEAK levels were associated with a lower prevalence of
pulmonary fibrosis and better pulmonary function in SSc patients.
This perturbed expression of TWEAK suggested some involve-
ment of the TWEAK pathway in the appearance of pulmonary
fibrosis, a well-known complication of the disease. Nevertheless
the mechanisms and the meaning of the elevation of sTWEAK
levels in this context remain to be determined (10).
FOR MONITORING THERAPIES TARGETING TNF SUPERFAMILY
MEMBERS
Currently, few autoimmune diseases can be cured with treatment.
In the last decade, TNF blocking agents have been developed for
the treatment of human diseases and have been very successful
in ameliorating disease signs and symptoms especially in patients
suffering from AICID like RA.
According to the work of Park et al. high sTWEAK levels have
been shown to correlate with TNF alpha levels in RA patients and
to reflect short-term response to etanercept, a biotherapy target-
ing TNF alpha (9). In fact, responders to etanercept showed a
significant decrease in sTWEAK levels at the 12th week of treat-
ment,whereas TWEAK levels in non-responders were not different
from their baseline levels. TWEAK is a member of TNF family.
Like TNF inhibition, TWEAK inhibition is an attractive thera-
peutic option in AICID. The results of the first study exploring
the safety and tolerability (phase I) of a TWEAK-blocking ther-
apy using the monoclonal antibody BIIB023 in patients with RA
have been recently published (3). They demonstrated that a single-
dose administration of BIIB023 was well tolerated in patients with
RA and was associated with a suppression of sTWEAK levels for
up to 28 days in the case of BIIB023 high dose. The efficacy of
BIIB023 (phase II) is now explored in the ongoing clinical trial
ATLAS (Anti-TWEAK in Lupus Nephritis patients) for patients
with lupus nephritis, a pathology that requires a more innova-
tive treatment than RA. In this context, quantification of soluble
TWEAK in anti-TWEAK treated patients is an interesting way for
managing BIIB023 administration.
TWEAK EVALUATION IN AICID: HOW TO PROCEED?
WHICH FORM OF TWEAK TO QUANTIFY: MEMBRANE AND/OR SOLUBLE
FORM?
TWEAK expression has been studied in various AICID animal
models and in humans (11–14). The main cellular sources of
TWEAK are cells from the monocyte/macrophage family includ-
ing immune infiltrating cells in tissues during inflammation.
TWEAK can expressed as a type II transmembrane protein or effi-
ciently cleaved to generate sTWEAK. Elevated levels of sTWEAK
can be found locally at the site of diseased tissue during AICID. The
presence of membrane-bound TWEAK has also been described
in human cells (15–17) but not in other studies of freshly iso-
lated peripheral blood mononuclear cells (PBMCs) from normal
subjects or patients with RA or SLE (Linda Burkly, personal com-
munication). Nevertheless the relevance of one form versus the
other is not yet elucidated. Modulation of the soluble form levels
rather than the membrane form is more frequently studied and
published.
WHICH SAMPLE TO COLLECT AND TO USE FOR TWEAK
QUANTIFICATION?
Soluble TWEAK is currently quantified in patient serum due to
the facility of routine blood collection by venous puncture. But
depending on the target tissue involved in AICID soluble TWEAK
could be quantified in various other body fluids such as syn-
ovial fluid (18), cerebrospinal fluid (17), or urine (19) and may
better reflect inflammatory activity in respectively the joint, the
brain, and the kidney. TWEAK expression during AICID has also
been studied in PBMCs by western blot and PCR. In SLE, eleva-
tion of TWEAK in PBMC is correlated with disease activity and
lupus nephritis (20). In SSc, the production of soluble TWEAK
by cultured PBMC is significantly diminished in patients with
more severe microvascular damage as indicated by capillaroscopy
(21). In the context of neuroinflammation, Serafini et al. reported
strong TWEAK expression on post-mortem MS brain tissue while
TWEAK was generally undetectable by immunohistochemistry in
the normal human brain white matter or cerebral cortex samples
(11). Even if these results are very interesting for further evaluation
of the role of TWEAK in MS physiopathology, these approaches
are not appropriate for routine diagnosis of MS. Desplat-Jégo et al.
have shown by using PBMC analysis after culture that TWEAK
is expressed at the cell surface of circulating monocytes during
MS and not during non-MS neurological inflammatory diseases
(17). This study also showed that TWEAK was detectable in the
serum and CSF of MS patients but found no significant difference
between the MS group and other clinical groups.
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Table 1 | “Normal” mean values and ranges for serum solubleTWEAK in humans determined by ELISA.
Publication reference ELISA kit manufacturer Number of control
healthy subjects tested
Serum solubleTWEAK
levels (pg/ml) Mean±SD (ranges)
Park et al. (9) Bender Medsystems 40 42.7±14.5
Yanaba et al. (10) Bender Medsystems 31 41.5±33.5
Yilmaz et al. (26) Bender Medsystems 55 445 (326–634)
Chorianopoulos et al. (27) Bender Medsystems 30 377 (310–432)
Xia et al. (28) Bender Medsystems 45 34.8 (15–54)
Kowal-Bielecka et al. (25) Bender Medsystems 48 294±147 (132–1015)
Turkmen et al. (29) Bender Medsystems 25 457 (320–538)
Desplat-Jégo, personal results Bender Medsystems 58 467 (200–866)
Schwartz et al. (5) Home-made ELISA 19 23.5 (17.3–27.1)
Llaurado et al. (30) R&D Systems 68 1636 (1146–3754) for men and 1401
(788–2422) for women
SD, standard deviation.
In RA, data on TWEAK/Fn14 expression in the synovium of
patients are available (12, 18) and support a high level of TWEAK
in RA synovial tissue concordant with the numerous activated
macrophages found in synovium during the disease and with the
beneficial effect of TWEAK blockade in a mouse model of RA.
TO QUANTIFY TWEAK ALONE OR ASSOCIATED WITH OTHER(S)
BIOLOGICAL PARAMETER(S)?
Panel-based approaches measuring a combination of biological
parameters are more and more used for routine biological diag-
nosis of human diseases. Very few studies have addressed the
diagnostic performance of associating TWEAK with one or several
other markers.
Moreno et al. have reported that soluble CD163/soluble
TWEAK ratio in peripheral blood is a more sensitive biomarker of
subclinical atherosclerosis than soluble CD163 or soluble TWEAK
alone (22). CD163 is a member of the scavenger receptor cysteine-
rich family now recognized as an immunomodulator of the ath-
erosclerotic plaque. It has been previously proposed that TWEAK
could specifically bind and neutralize TWEAK and that CD163-
expressing monocytes/macrophages were able to bind and inter-
nalize exogenous TWEAK (23). However this interaction has
recently failed to be confirmed (24). Nonetheless, Kowal-Bielecka
et al. have recently shown that a high serum soluble CD163/soluble
TWEAK ratio is associated with lower risk of digital ulcers but with
a more severe skin disease in patients with SSc (25).
In the case of spot urine exploration of soluble TWEAK, it is
recommended to normalize TWEAK levels to urinary creatinine
measured in the same spot urine since creatinine excretion rate
into the urine is relatively constant and allows to compensate for
the variability in the volume of urine and the concentrations of
soluble TWEAK from void to void (5).
TWEAK EVALUATION IN AICID: HOW TO DEFINE
PATHOLOGICAL VALUES?
In the first place, normal value ranges have to be determined
prior to the definition of pathological values for sTWEAK lev-
els in humans. A threshold for pathological TWEAK levels has
to be established. It is not an easy task. Different ranges of nor-
mal values issued from various laboratory teams are available
(Table 1) and there is obviously a lack of homogeneity. The differ-
ences observed in soluble TWEAK levels in healthy control subjects
depend presumably on various parameters: age, sex, ethnic origin
of the recruited control group, pre-analytical conditions especially
sample storage conditions before analysis, the technical character-
istics of the ELISA kits, nature of TWEAK epitopes recognized by
anti-TWEAK antibodies, capacity of soluble TWEAK to trimerize
etc. Table 1 summarizes the data obtained by 10 teams and shows
the difficulty in obtaining to date consensual normal values for
sTWEAK levels.
In urine, LN patients have been compared with control subjects
but data obtained in this latter group was detailed by only one
team in 23 healthy volunteers with a reference value for uTWEAK
of 5.67 pg/mg of creatinine (interquartile range: 3.10) (5, 6, 19).
In the case of other biological fluids (CSF, synovial fluid) data
are lacking to establish normal ranges especially because collec-
tions of such fluids are invasive and not allowed in control healthy
subjects by ethic committees.
IN CONCLUSION
On the one hand, quantification of uTWEAK in AICID seems
to be an interesting tool in the follow-up of disease activity
especially in lupus nephritis. On the other hand it is prema-
ture to propose sTWEAK as a diagnostic tool of AICID due to
the lack of specificity for one disease in particular. Moreover
studies analyzing diagnostic performance of serum sTWEAK are
still needed. sTWEAK assay is nevertheless useful in the follow-
up of anti-TWEAK biotherapies and perhaps could be useful
in the follow-up of anti-TNFα therapies but this latter point
needs to further be evaluated. At this point, the most impor-
tant criticism concerning TWEAK evaluation in AICID is the
difficulty in obtaining consensual ranges for normal values of
sTWEAK. Reagents for the assessment of TWEAK levels are
now commercially available for research purposes only. How-
ever, standardization of the proposed kits is absolutely required
all the more because free soluble TWEAK is a “sticky” pro-
tein difficult to manipulate based on experience from our team
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and others (31). Moreover comparison between studies using
different reagents must be conducted carefully. It is our opin-
ion that the standardization of data collection is critical to
further evaluate the clinical utility of TWEAK as a promising
biomarker.
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